New real-world evidence on the MSDA Test published in The Multiple Sclerosis Journal – ET&C. Read the press release

Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies